Late-breaking clinical trials announced for TCT 2026 in San Diego
TCT 2026, the annual Transcatheter Cardiovascular Therapeutics (TCT) meeting from the Cardiovascular Research Foundation, is scheduled to feature the latest science in interventional cardiology and structural heart interventions. The conference will include 28 late-breaking studies that highlight advances in minimally invasive interventions, pharmaceutical therapies and breakthrough technologies designed to prevent, manage and treat cardiovascular disease.
Read on for the the full schedule for these late-breaking studies:
Sunday, Nov. 1, 10:45 a.m. — 12:13 p.m., Main Arena 4
Late-Breaking Clinical Trials: Session I, in Collaboration with The Lancet
• Coronary CT Angiography-Guided vs. IVUS-Guided PCI: The Randomized P4 Trial. Presented by Carlos Collet.
• Sirolimus Coated Balloons vs. Drug-Eluting Stents in Native Coronary Vessels: The TRANSFORM II Randomized Trial. Presented by Bernardo Cortese.
• A Randomized Trial of Higher vs. Lower Dose Heparin for PCI: The HD-PCI Trial. Presented by Sanjit Jolly.
• Coronary Sinus Reducer for Refractory Angina in ANOCA: A Randomized Double-Blind Sham-Controlled Trial (REMEDY-PILOT). Presented by Kevin Cheng.
Sunday, Nov. 1, 2:15 — 3:45 p.m., Main Arena 5
Late-Breaking Clinical Science: Session I, in Collaboration with Circulation
• Characteristics and Clinical Outcomes of Tricuspid Regurgitation in the Community: Insights from a Real-World Cohort of 180,977 Men and Women. Presented by Rebecca Hahn.
• Transcatheter Tricuspid Valve Replacement with the LuX-Valve Plus System vs. Medical Therapy for Severe TR: The Randomized TRAVEL III Trial. Presented by Junbo Ge.
• Transcatheter Tricuspid Valve Intervention in Heart Failure: Key Subgroup Results from the TRIC-I-HF-DZHK24 Trial. Presented by Jörg Hausleiter.
• One-Year Outcomes with the Amulet 360 Device for Left Atrial Appendage Closure: The VERITAS Amulet 360 Study. Presented by Dhanunjaya Lakkireddy.
• Left Atrial Appendage Closure vs. Contemporary Medical Therapy for Stroke Prevention in AF (LANTERN): An IPD Meta-Analysis of Randomized Trials. Presented by Rohin Reddy.
Monday, Nov. 2, 9:40 — 11:10 a.m., Main Arena 10
Late-Breaking Clinical Trials: Session II, in Collaboration with the New England Journal of Medicine
• TAVR or Clinical Surveillance for Moderate Aortic Stenosis: Primary Results of the PROGRESS Randomized Trial. Presented by Philippe Genereux.
• Transcatheter Tricuspid Valve Repair with the PASCAL System vs. Medical Therapy for Severe, Symptomatic Tricuspid Regurgitation: Clinical and Health Status Outcomes from the CLASP II TR Randomized Trial. Presented by Charles Davidson and Suzanne Arnold.
• Global Burden and Outcomes of Degenerative Mitral Valve Disease: A 30-Year Analysis of the Global Burden of Disease Study. Presented by Juan Granada.
• Antithrombotic Monotherapy After Left Atrial Appendage Occlusion: Primary Results of the SIMPLAAFY Randomized Trial. Presented by Saibal Kar.
Monday, Nov. 2, 2:15 — 3:45 p.m., Main Arena 12
Late-Breaking Clinical Science: Session II, in Collaboration with the European Heart Journal
• One-Year Outcomes of the PeriSorb Bioresorbable Vascular Scaffold vs. Drug-Coated Balloon for Superficial Femoral Artery Disease: A Multicenter Randomized Trial. Presented by Yuan Che.
• Three-Year Outcomes of Sirolimus vs. Paclitaxel-Coated Balloons for Femoropopliteal Artery Disease: The Randomized SIRONA Trial. Presented by Ulf Teichgräber.
• Impact of Non-Culprit Lesion Severity on the Utility of Functional Coronary Angiography in Patients with STEMI and Multivessel Disease: The AIR STEMI Randomized Trial. Presented by Simone Biscaglia.
• Angiography-Derived FFR Versus vs. Wire-Based FFR to Guide Coronary Revascularization: The LIPSIA-STRATEGY Trial. Presented by Nicolas Majunke.
• Intracoronary Delivery of Nicorandil for Prevention of No-Reflow Patients Undergoing Primary PCI for STEMI: A Multicenter Randomized Trial. Presented by Takashi Muramatsu.
Tuesday, Nov. 3, 10:45 a.m. — 12:15 p.m., Main Arena 18
Late-Breaking Clinical Trials: Session III, in Collaboration with the Journal of the ACC
• Angiography-Derived FFR vs. Usual Care for Lesion Selection and Optimization in All-Comers PCI: Final Results of the PIONEER IV Randomized Trial. Presented by Patrick Serruys.
• Platelet Function Testing to Guide P2Y12 Inhibitor De-Escalation After ACS: The EPIC17-VERONICA Randomized Trial. Presented by
Iñigo Lozano.
• Safety and Effectiveness of Radiofrequency Renal Denervation in the United States: Primary Results of the SPYRAL AFFIRM Post-Approval Study. Presented by David Kandzari.
• Single vs. Double ProGlide Devices for Access Site Closure After Transfemoral TAVR: The SINGLE-CLOSURE Trial. Presented by Jian’an Wang.
• The ProtEmbo Cerebral Protection System During TAVR: Final Results of the Randomized PROTEMBO IDE Trial. Presented by Susheel Kodali.
Tuesday, Nov. 3, 12:20 — 1:50 p.m., Main Arena 19
Late-Breaking Clinical Science: Session III, in Collaboration with the Journal of the AMA
• Transcatheter vs. Surgical AVR for Symptomatic, Severe Aortic Regurgitation: One-Year Outcomes from a Multicenter Randomized Trial. Presented by Xiaoping Peng.
• Transcatheter Aortic Valve Replacement with the JenaValve Trilogy System for Aortic Regurgitation in Patients with a Left Ventricular Assist Device: The JENA-VAD Study. Presented by Ravi Ramana.
• Economic Outcomes and Cost-Effectiveness of TAVR for Asymptomatic Severe Aortic Stenosis: Results from the EARLY TAVR Trial. Presented by Neel Butala.
• Routine Post-Dilation vs. Conventional Deployment for Balloon-Expandable TAVR: The Randomized DUOTAP Trial. Presented by Maximilian Autherith.
• Percutaneous Transcatheter Mitral Valve Replacement in Patients with Symptomatic Mitral Regurgitation: 2-Year Outcomes from the ENCIRCLE Trial. Presented by John G. Webb.
More information
TCT 2026 runs from Oct. 31 to Nov. 3 in San Diego. Click here for additional details about the conference and here for more about these late-breaking presentations.
Dave Fornell has covered healthcare for more than 17 years, with a focus in cardiology and radiology. Fornell is a 5-time winner of a Jesse H. Neal Award, the most prestigious editorial honors in the field of specialized journalism. The wins included best technical content, best use of social media and best COVID-19 coverage. Fornell was also a three-time Neal finalist for best range of work by a single author. He produces more than 100 editorial videos each year, most of them interviews with key opinion leaders in medicine. He also writes technical articles, covers key trends, conducts video hospital site visits, and is very involved with social media. E-mail: [email protected]